Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPINEPHRINE REFORMULATION UNDER CFC LAW PROVIDES RESEARCH OPPORTUNITY

This article was originally published in The Tan Sheet

Executive Summary

EPINEPHRINE REFORMULATION UNDER CFC LAW PROVIDES RESEARCH OPPORTUNITY to answer questions about the OTC product's use and patient population, Nonprescription Drugs Advisory Committee member Alan Sinaiko, MD, University of Minnesota Medical School, suggested at a Nov. 14 meeting with the Pulmonary-Allergy Advisory Committee, Sinaiko suggested that reformulation would provide "a great opportunity to see who is taking these OTC inhalers."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083448

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel